BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 22301780)

  • 21. FOXA1 represses the molecular phenotype of basal breast cancer cells.
    Bernardo GM; Bebek G; Ginther CL; Sizemore ST; Lozada KL; Miedler JD; Anderson LA; Godwin AK; Abdul-Karim FW; Slamon DJ; Keri RA
    Oncogene; 2013 Jan; 32(5):554-63. PubMed ID: 22391567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New strategies in estrogen receptor-positive breast cancer.
    Johnston SR
    Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CBP mediates NF-κB-dependent histone acetylation and estrogen receptor recruitment to an estrogen response element in the BIRC3 promoter.
    Pradhan M; Baumgarten SC; Bembinster LA; Frasor J
    Mol Cell Biol; 2012 Jan; 32(2):569-75. PubMed ID: 22083956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
    Yau C; Benz CC
    Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.
    Van Laere SJ; Van der Auwera I; Van den Eynden GG; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
    Br J Cancer; 2007 Sep; 97(5):659-69. PubMed ID: 17700572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
    Chen AC; Migliaccio I; Rimawi M; Lopez-Tarruella S; Creighton CJ; Massarweh S; Huang C; Wang YC; Batra SK; Gutierrez MC; Osborne CK; Schiff R
    Breast Cancer Res Treat; 2012 Jul; 134(2):583-93. PubMed ID: 22644656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
    Keklikoglou I; Koerner C; Schmidt C; Zhang JD; Heckmann D; Shavinskaya A; Allgayer H; Gückel B; Fehm T; Schneeweiss A; Sahin O; Wiemann S; Tschulena U
    Oncogene; 2012 Sep; 31(37):4150-63. PubMed ID: 22158050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptor status heterogeneity in breast cancer tumor: role in response to endocrine treatment.
    Malavasi E; Giamas G; Gagliano T
    Cancer Gene Ther; 2023 Jul; 30(7):932-935. PubMed ID: 37085602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
    Ma CX; Bose R; Ellis MJ
    Adv Exp Med Biol; 2016; 882():125-54. PubMed ID: 26987533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells.
    Buchwalter G; Hickey MM; Cromer A; Selfors LM; Gunawardane RN; Frishman J; Jeselsohn R; Lim E; Chi D; Fu X; Schiff R; Brown M; Brugge JS
    Cancer Cell; 2013 Jun; 23(6):753-67. PubMed ID: 23764000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.
    Nakshatri H; Bhat-Nakshatri P; Martin DA; Goulet RJ; Sledge GW
    Mol Cell Biol; 1997 Jul; 17(7):3629-39. PubMed ID: 9199297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.
    Harvell DM; Spoelstra NS; Singh M; McManaman JL; Finlayson C; Phang T; Trapp S; Hunter L; Dye WW; Borges VF; Elias A; Horwitz KB; Richer JK
    Breast Cancer Res Treat; 2008 Dec; 112(3):475-88. PubMed ID: 18327671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.
    Chan HJ; Petrossian K; Chen S
    J Steroid Biochem Mol Biol; 2016 Jul; 161():73-83. PubMed ID: 26277097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
    Amin R; Morita-Fujimura Y; Tawarayama H; Semba K; Chiba N; Fukumoto M; Ikawa S
    Mol Oncol; 2016 Apr; 10(4):575-93. PubMed ID: 26704768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.
    Biswas DK; Iglehart JD
    J Cell Physiol; 2006 Dec; 209(3):645-52. PubMed ID: 17001676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
    Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
    Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NFκB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms.
    Frasor J; El-Shennawy L; Stender JD; Kastrati I
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 3(0 3):235-9. PubMed ID: 25450861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF1 supports glycolytic metabolism through the estrogen receptor in endocrine-resistant and obesity-associated breast cancer.
    Castillo-Castrejon M; Sankofi BM; Murguia SJ; Udeme AA; Cen HH; Xia YH; Thomas NS; Berry WL; Jones KL; Richard VR; Zahedi RP; Borchers CH; Johnson JD; Wellberg EA
    Breast Cancer Res; 2023 Aug; 25(1):99. PubMed ID: 37608351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.
    Brechbuhl HM; Finlay-Schultz J; Yamamoto TM; Gillen AE; Cittelly DM; Tan AC; Sams SB; Pillai MM; Elias AD; Robinson WA; Sartorius CA; Kabos P
    Clin Cancer Res; 2017 Apr; 23(7):1710-1721. PubMed ID: 27702820
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.